Navigation Links
Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
Date:9/27/2011

continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which a
'/>"/>

SOURCE Masimo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
2. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. LTCPA Study Quantifying Unused Medicare Part D Drugs in Skilled Nursing Facilities Published in The Consultant Pharmacist
5. Zertane™ Clinical Results Published in the Journal European Urology
6. REMEDIAL II Trial of PLCs RenalGuard® Article Published in Circulation
7. Newly-Published Colchicine Safety Data Provide First Evidence-Based Dosing Guidance to Avoid Potentially Serious Interactions With Commonly Prescribed Drugs
8. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
9. PK Study Comparing Upsher-Smiths Extended-Release Topiramate Formulation (USL255) With Topamax® Published Online In Epilepsia
10. Study Published in Journal of Vascular Surgery Confirms Superiority of Artegraft BCA to Cuffed ePTFE for Hemodialysis Access
11. Largest Multi-Centre Evaluation of Radioembolization Using Sir-Spheres for Patients With Inoperable Primary Liver Cancer Published in Hepatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)... , July 23, 2014  The management ... CBRX ) will hold a conference call on ... the second quarter ended June 30, 2014.  The ... 31, 2014Time: , 8:30 am EDTDial-in numbers: , ... or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... Global healthcare company GSK reports Q2 results ... price competition and supply disruptions to its Consumer business. ... out that the company is very much in transition, citing ... about long-term prospects as well as the investments being ... Simon Dingemans adds that the company is reining ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... ... with blogs, groups, forums, photos and videos , ... Norfolk, Va. (PRWEB) November 2, 2009 -- HealthCareerWeb.com, a full service healthcare ... online health care jobs section with its medical professional network . , ...
... 2 STANDUP FOR KIDS has been chosen by STAR ... businesses are being asked to join forces for charity ... for November,s National Homeless Youth Awareness Month. Local business ... OF THE NEIGHBORHOOD, are displaying posters and encouraging their customers ...
... On Thursday, November 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. ... (Nasdaq and MTA: CTIC) management team will host a conference ... , , Conference Call Numbers, ... p.m. Central European/5:30 a.m. Pacific Time, 1-877-941-6010 ...
... , the journal of the American Academy of Ophthalmology ... surgery is likely to benefit patients with age-related macular ... a clinical trial showing that the steroid triamcinolone may ... when standard treatment fails, and on the public,s use ...
... Nov. 1 Schering-Plough Corporation (NYSE: SGP ) ... with boceprevir combination therapy in patients with chronic hepatitis ... were presented at the American Association for the Study ... 30-Nov. 3. , Boceprevir is an investigational ...
... body fat means greater survival odds, researcher says , SUNDAY, Nov. ... are much more likely to die than other people on dialysis, ... study has found. , Researchers measured body fat percentage in 671 ... rate for people with less than 10 percent body fat was ...
Cached Medicine News:Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 2Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 3Health News:Local Businesses Unite, Calling an End to Youth Homelessness 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 4Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 5Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 6Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 7Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 8Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 9Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 10Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 11
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... Digital Pulse Oximeter monitors SpO2, ... It is designed to provide ... patients. The device rejects spontaneous ... the operator of excess artifacts ...
... The 8600FO is designed to ... MRI users for patient safety ... Fiber Optic Sensors and Cables ... is eliminated, as well as ...
... The 8600 Series Tabletop/Portable ... simple universal tool for patient ... continuous monitoring, the 8600 has ... professionals worldwide and is recognized ...
Medicine Products: